Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

AstraZeneca antibody cocktail Evusheld will face imminent competition in Australia, says GlobalData

Australia recently granted provisional determination for AstraZeneca’s COVID-19 monoclonal antibody (mAb) cocktail postexposure prophylaxis (PEP) therapy Evusheld (tixagevimab + cilgavimab / AZD7442). On expected successful provisional approval and launch in early 2022, it faces competition with a crowded COVID-19 armory of mAb and oral anti-viral therapies, says GlobalData, a leading data and analytics company. So […]
Read more

Chinese pharma companies eye strategic alliances to bring innovative siRNA-based therapeutics, observes GlobalData

The overall potential of siRNA-based therapeutics has attracted Chinese pharma companies to tap opportunities and bring promising innovative therapies across the globe. Against this backdrop, the Chinese pharma companies have increased their focus towards the siRNA pipeline through strategic alliances*, finds GlobalData, a leading data and analytics company. China pharma companies have executed four deals […]
Read more

Indian pharma companies gearing up to grab opportunities in global supply of oral COVID-19 drugs, observes GlobalData

Indian pharma companies have already occupied pole position in the supply of repurposed COVID-19 drugs globally. With the launch of new innovative COVID-19 oral drugs, Indian companies are again expected to grab opportunities in the global supply of oral COVID-19 drugs, says GlobalData, a leading data and analytics company. Several countries are observing increasing cases […]
Read more

Psilocybin has potential to become a breakthrough therapy for treatment-resistant depression if safety concerns are resolved, says GlobalData

Compass Pathways recently announced positive topline results for COMP360 (psilocybin), from the largest clinical trial to date, in conjunction with psychological support from specially trained therapists, for treatment-resistant depression (TRD). GlobalData, a leading data and analytics company, believes that this clinical trial demonstrates the potential of psilocybin to become a breakthrough therapy for TRD if […]
Read more

Telemedicine will not fully replace in-person consultations, says GlobalData

Moving towards digitalization in healthcare was on many governments’ agendas prior to the COVID-19 pandemic, but issues with the legislative landscape, reimbursement, and acceptance prevented telehealth from being fully integrated into healthcare systems, says GlobalData. The leading data and analytics company notes that, while telemedicine showcased its potential to become an essential element of modern […]
Read more

UK lags in clinical trial activity despite other countries recovering to pre-pandemic levels, says GlobalData

The COVID-19 pandemic has had a seismic impact in clinical trial investigations, halting studies in their tracks. Yet, while trial activity has since recovered to pre-pandemic levels in Australia and the US, the UK remains behind, according to reporting by Andrew Hillman, healthcare and pharmaceuticals data journalist at GlobalData, a leading data and analytics company. […]
Read more

Innovative therapeutic classes to drive NMOSD market in China at 20.9% CAGR through 2030, forecasts GlobalData

The neuromyelitis optica spectrum disorder (NMOSD) therapeutics market is highly genericized, with corticosteroids and immunosuppressants currently accounting for the highest portion of prescribed drugs in China. However, the introduction of more innovative and effective classes of therapies is expected to drive increasing sales through 2030 at a compound annual growth rate (CAGR) of 20.9%, according […]
Read more

Kyowa Kirin’s Poteligeo will be a game-changer for Sézary syndrome treatment in the UK, says GlobalData

Following today’s news (11 November) that the National Institute for Health and Care Excellence (NICE) has recommended Kyowa Kirin’s Poteligeo for the treatment of adult patients with relapsed mycosis fungoides (MF) and Sézary syndrome (SS), types of blood cancer with skin involvement called cutaneous T-cell lymphoma (CTCL); Sakis Paliouras, PhD, Senior Oncology & Hematology Analyst […]
Read more

Significant scope for key players in Japan CKD market to strengthen digital presence, says GlobalData

Chronic kidney disease (CKD) is associated with an increased risk of cardiovascular (CV) disease or the need for dialysis or kidney transplantation. Currently, AstraZeneca’s sodium-glucose cotransporter 2 (SGLT2) inhibitor Forxiga (dapagliflozin propanediol) is the only marketed therapy available for the treatment of CKD in Japan. Against this backdrop, key players in Japan’s CKD market have […]
Read more

Caution must be used when addressing anti-vaxxers as frustrated comments will just drive the very gap we are trying to bridge, says GlobalData

Following the news that Pfizer CEO Albert Bourla called people who spread misinformation on COVID-19 vaccines ‘criminals’, Emily Martyn, MPH, Healthcare Analyst at GlobalData, a leading data and analytics company, offers her view: “It is understandable that the pharmaceutical industry is frustrated, however, it is important to remember that the unvaccinated community, including anti-vaxxers, are […]
Read more

Gut-skin axis may hold the answer to hidradenitis suppurativa, says GlobalData

At the end of September, results were presented at the European Academy of Dermatology and Venereology (EADV) Congress from a study exploring patterns in the rare skin disease hidradenitis suppurativa (HS). Currently, effective therapies for the disease are limited, leading to great unmet need for better treatment options. HS-specific patterns in patients’ skin and gut microbiomes in this study suggest that similar to psoriasis (PsO), HS may be a good candidate indication for […]
Read more

Cibinqo impending approval to shake up EU atopic dermatitis market with heightened competition, says GlobalData

Pfizer’s Cibinqo (abrocitinib) is likely to be approved by the EU for the treatment of ‘moderate to severe’ atopic dermatitis (AD) by this year-end ensuing a positive European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) opinion on 15 October 2021. Following the approval of Lilly/Incyte’s Olumiant (baricitinib), and more recently AbbVie’s […]
Read more
1 … 55 56 57 58 59 … 110